Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study

Key Points

• Overall response rate with the treatment is high for patients with RAS-mutant metastatic colorectal cancer.
• Assessment shows a manageable safety profile during first-line treatment with tislelizumab, XELOX, and bevacizumab.
• Phase II analysis tested this chemo-immunotherapy combination in RAS-mutant mCRC and produced encouraging results.
• Further investigation is warranted, highlighting the need for phase III trials to confirm effectiveness of the treatment.